Researchers are testing a small interfering RNA molecule designed to reduce prion protein production. This marks the first human trial for this treatment.
Researchers are testing a small interfering RNA molecule designed to reduce prion protein production. This marks the first human trial for this treatment.
@newsen.bsky.social
@jia-jintegragri.bsky.socialEngineered ferritin nanocages for efficient #siRNA delivery and potent #gene silencing in #plants
🎓led by Prof. Xueyong Yang from CAAS
🌟https://doi.org/10.1016/j.jia.2026.05.063
#horticulture #plantscience
@discoveripo.bsky.socialADARx Pharmaceuticals, Inc. filed for an IPO
ADARx Pharmaceuticals has filed for an IPO. The biotech firm is focused on innovative siRNA therapeutics for various diseases, including obesity and neurodegenerative…
Biotech
#IPO #Biotech #PharmaceuticalPreparations #UnitedStates #IPONews #siRNA
@prof-clark.bsky.socialADARx’s planned IPO could signal growing confidence in complement therapeutic, with a CFB-targeting siRNA advancing into AMD geographic atrophy. Could durable complement suppression be the next step for AMD? #AMD #Complement #siRNA #GeneSilencing buff.ly/K4O3O33
@tokyo-days.bsky.social
@new3rd.bsky.social